Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol add-on therapy versus placebo in refractory childhood epilepsy
NL-OMON59029Phase 3Not yet recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in epilepsy (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Primary efficacy endpoint. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
epilepsy
Beyond the preview
Go deeper on NL-OMON59029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59029.